Myeloma 2016

MMRF presents highlights for patients at Myeloma 2016

Isatuximab for multiple myeloma – promising results and next steps

Tolerability of monoclonal antibodies in multiple myeloma

The biology of the plasma cell and drug targets in multiple myeloma

Clinical management of venetoclax in multiple myeloma

The importance of the microenvironment in multiple myeloma

Perspectives on future paths to cure multiple myeloma

Update on trametinib for multiple myeloma

LCL161 – a new approach to treating multiple myeloma

Mechanism of action of daratumumab

Myeloma 2016: Panel discussion on novel treatments

Myeloma 2016: Panel discussion on the new treatment paradigm

Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma

How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma

PET-CT vs MRI in multiple myeloma

The impact of new drugs and the changing role of transplants in multiple myeloma